In the News
Diabetes remission after bariatric surgery may be more likely in younger patients with shorter disease duration
Long-term results from the Longitudinal Assessment of Bariatric Surgery suggested that diabetes remission is more likely after bariatric surgery performed soon after diagnosis, when diabetes medication burden is low and beta-cell function is preserved, study authors noted.
Balanced crystalloids may be preferred for acute resolution of diabetic ketoacidosis
A small subgroup analysis of two randomized trials found that median time to resolution of diabetic ketoacidosis was 13 hours in patients who received balanced crystalloids versus nearly 17 hours in those who received saline.
Patients with type 2 diabetes and all risk factors controlled still have increased CVD risk
Risk factor control was more strongly associated with mortality risk among patients with cardiorenal disease than those without, according to a retrospective British study.
MKSAP quiz: Glycemic testing
This month's quiz asks readers about additional testing for a 72-year-old woman with a fasting plasma glucose level of 130 mg/dL (7.2 mmol/L) and an HbA1c level of 5.4%.
Spotlight on heart failure and diabetes
A new study validated a score for predicting risk of heart failure in patients with type 2 diabetes, while another looked at historical trends in heart failure hospitalizations in U.S. diabetes patients.
Peripheral neuropathy associated with increased mortality risk, irrespective of diabetes status
Patients with both diabetes and peripheral neuropathy had the highest risk of death during the study's 13-year follow-up, but the next highest rate was in patients with peripheral neuropathy but no diabetes, followed by those with diabetes without peripheral neuropathy.
Semaglutide showed some benefit in patients with NASH, liver fibrosis
Significantly more patients taking the glucagon-like peptide-1 receptor agonist had resolution of their nonalcoholic steatohepatitis (NASH) than those taking placebo, but rates of liver fibrosis improvement were similar between groups, an industry-funded trial found.
Some glucose-lowering drugs reduce HbA1c more than others
A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
Continuous glucose monitoring reduced hypoglycemia over 6 months
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.